- The majority of NETs have somatic mutations in MEN1 and CDKN1B, and genes involved in the PI3K/AKT/mTOR signaling pathway, and/or overexpression of growth factors and their receptors such as VEGF, VEGFR, PDGF, and PDGFR that can be targeted for therapy.